Yes, you can discontinue ceftazidime, clindamycin, and tigecycline and switch to ceftazidime-avibactam plus aztreonam for enhanced gram-negative coverage, particularly if you are dealing with carbapenem-resistant Enterobacterales (CRE) producing metallo-β-lactamases (MBLs).
Rationale for the Switch
The combination of ceftazidime-avibactam plus aztreonam is specifically recommended by ESCMID guidelines for severe infections caused by MBL-producing CRE 1. This combination provides synergistic activity against extensively drug-resistant gram-negative pathogens that your current regimen likely does not adequately cover.
Why Your Current Regimen is Suboptimal
- Tigecycline should NOT be used for bloodstream infections (BSI) or hospital-acquired/ventilator-associated pneumonia (HAP/VAP) due to poor outcomes 1
- Ceftazidime monotherapy is inadequate for carbapenem-resistant organisms
- Clindamycin provides no gram-negative coverage and is irrelevant for this indication
The Ceftazidime-Avibactam + Aztreonam Combination
This combination works through a unique mechanism:
- Avibactam inhibits serine carbapenemases (KPC, OXA-48) but NOT metallo-β-lactamases
- Aztreonam remains stable against MBLs but is hydrolyzed by serine carbapenemases
- Together, avibactam protects aztreonam from serine carbapenemases while aztreonam provides activity against MBL-producers 1
Evidence Supporting This Combination
A prospective observational study of 102 patients with MBL-producing CRE bacteremia (82 NDM, 20 VIM strains) demonstrated that ceftazidime-avibactam plus aztreonam was associated with:
- 63% lower 30-day mortality (HR 0.37,95% CI 0.13-0.74)
- Reduced clinical failure rates
- Shorter hospital stays 1
Recent data shows synergy in 98.8% of Klebsiella spp. and 95% of E. coli isolates, including pan-drug resistant strains 2. In critically ill ICU patients, this combination demonstrated synergy in 62.5% of XDR isolates with microbiological clearance achieved exclusively in synergy-positive cases 3.
Dosing Recommendations
Ceftazidime-Avibactam
- 2.5 g IV every 8 hours, infused over 3 hours (prolonged infusion improves outcomes) 1, 4
- Adjust for renal function 5
Aztreonam
- 2 g IV every 8 hours for severe infections
- Standard infusion over 20-60 minutes 6
Critical Considerations
When This Combination is Most Appropriate
- Confirmed or suspected MBL-producing CRE (NDM, VIM, IMP)
- Severe infections: BSI, HAP/VAP, complicated intra-abdominal infections
- Organisms resistant to ceftazidime-avibactam alone
- Extensively drug-resistant (XDR) or pan-drug resistant (PDR) isolates 1
Antibiotic Stewardship Caveat
ESCMID guidelines emphasize that new β-lactam/β-lactamase inhibitor combinations should be reserved for extensively resistant bacteria 1. If your isolate is susceptible to older agents (aminoglycosides, polymyxins) and the infection is non-severe, consider those first for stewardship reasons.
Monotherapy vs. Combination
For organisms susceptible to ceftazidime-avibactam alone (KPC-producers without MBLs), monotherapy is sufficient and combination therapy is NOT recommended 1. The combination is specifically indicated when:
- MBL production is confirmed or suspected
- Resistance to ceftazidime-avibactam develops during therapy
- Organisms are resistant to all other available options
Physical Compatibility
Ceftazidime-avibactam is physically compatible with aztreonam in Y-site administration, so they can be given through the same IV line 7.
Common Pitfalls to Avoid
- Don't use this combination empirically without considering local resistance patterns and individual patient factors
- Don't continue tigecycline for serious gram-negative infections—it has poor outcomes in BSI and pneumonia 1
- Don't forget renal dose adjustments for both agents 5
- Don't use carbapenem-based combinations if new β-lactam/β-lactamase inhibitors are available and active 1
- Ensure prolonged infusion (3 hours) of ceftazidime-avibactam for optimal pharmacodynamics 1